Products Etanercept
Etanercept Phase 3 Completed 📈 Rising Pediatric Plaque Psoriasis
Pediatric Plaque Psoriasis
Aug 11, 2005 → Aug 16, 2017
About Etanercept Etanercept is a phase 3 stage product being developed by Amgen for Pediatric Plaque Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT00141921. Target conditions include Pediatric Plaque Psoriasis.
Clinical Trials (20) NCT ID Phase Status Start Completion Indication NCT00111111 Phase 3 Completed — — Psoriasis NCT05135312 Approved UNKNOWN Aug 9, 2021 Aug 8, 2022 Psoriasis NCT02749370 Approved Completed May 18, 2016 Dec 6, 2017 Plaque Psoriasis NCT02274792 Approved Completed Jan 1, 2015 Nov 1, 2015 Plaque Psoriasis NCT01971346 Approved Completed Mar 13, 2014 Nov 1, 2017 Psoriasis NCT01543204 Approved Terminated Feb 1, 2012 May 29, 2015 Psoriasis NCT01132235 Approved UNKNOWN Apr 1, 2010 Dec 1, 2010 Psoriasis NCT01009879 Approved Withdrawn Nov 1, 2009 Feb 1, 2012 Rheumatoid Arthritis NCT00833729 Approved Completed Feb 1, 2009 Feb 1, 2010 Plaque Psoriasis NCT00640393 Approved Completed Apr 1, 2008 Mar 1, 2010 Psoriasis Vulgaris NCT01053819 Approved Completed Sep 1, 2007 Apr 1, 2012 Psoriasis NCT00477191 Pre-clinical Terminated May 1, 2007 Dec 1, 2013 Psoriasis NCT00585650 Phase 1/2 Completed May 1, 2007 May 1, 2008 Psoriasis NCT00413452 Phase 3 Completed Dec 1, 2006 Oct 1, 2007 Rheumatoid Arthritis NCT00361634 Phase 1 Completed Sep 1, 2006 Mar 1, 2010 Rheumatoid Arthritis NCT00333034 Phase 3 Completed Jun 1, 2006 May 1, 2007 Psoriasis NCT00322439 Pre-clinical Completed May 1, 2006 Feb 8, 2013 Psoriasis NCT00332332 Approved Completed Mar 1, 2006 Feb 1, 2010 Psoriasis NCT00346294 Approved Completed Jan 1, 2006 Jul 1, 2006 Rheumatoid Arthritis NCT00965666 Phase 1 Completed Oct 1, 2005 Oct 1, 2010 Fanconi Anemia
Product Company Stage Hype Score Ramucirumab Eli Lilly Phase 1 erlotinib + etoposide Astellas Pharma Phase 2 Mitoxantrone Hydrochloride Liposome + Irinotecan + Vincristine Sun Pharmaceutical Phase 1 Perampanel Oral Suspension + Perampanel Tablet Eisai Phase 2 Eribulin Mesylate Eisai Phase 1 Decitabine + Decitabine Eisai Phase 2 Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily Sumitomo Pharma Phase 1 Remimazolam Tosilate for injection + Propofol Injection Jiangsu Hengrui Medicine Phase 2/3 Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or Linezolid AstraZeneca Phase 2/3 candsartan cilexetil AstraZeneca Phase 3 Durvalumab / Tremelimumab Combination Therapy AstraZeneca Phase 1/2 Rotavirus Vaccine Merck Pre-clinical basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroids Novartis Phase 3 VAL489 + VAL489 matching placebo Novartis Phase 3 LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696 Novartis Phase 2/3 Everolimus Novartis Phase 2 Corticosteroids + Cyclosporine + mycophenolate mofetil Roche Phase 2 Entecavir + Lamivudine + Pegylated Interferon Alfa-2A Roche Phase 3 Blinatumomab for Injection Amgen Phase 1 Denosumab Amgen Phase 3
Other Products from Amgen